Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS‐CoV‐2 Infection in Older Adults During the JN.1 Lineage‐Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023–1 March 2024

Lore Merdrignac(Helicon Foundation), Silke Buda(Robert Koch Institute), Mariëtte Hooiveld(Netherlands Institute for Health Services Research), Mihaela Lazăr, Marlena Kaczmarek(European Centre for Disease Prevention and Control), Marine Maurel, Verónica Gomez(National Institute of Health Dr. Ricardo Jorge), Nuno Verdasca(National Institute of Health Dr. Ricardo Jorge), Gergő Túri(Semmelweis University), Tove Samuelsson Hagey(Public Health Agency of Sweden), Esther Kissling, Marie‐Anne Rameix‐Welti(Inserm), Ana Paula Rodrigues(Microsoft (Brazil)), Frederika Dijkstra(National Institute for Public Health and the Environment), Adam Meijer(National Centre for Infectious Diseases), Daniel Castrillejo(Consejería de Educación de la Junta de Castilla y León), Aryse Melo(National Institute of Health Dr. Ricardo Jorge), Sanja Filipović(Hrvatski zavod za javno zdravstvo), Beatrix Oroszi, Ralf Dürrwald(IDT Biologika (Germany)), Charlotte Lanièce Delaunay(Helicon Foundation), Sabrina Bacci(European Centre for Disease Prevention and Control), Charlene Bennett(University College Dublin), Lorena Vega‐Piris(Instituto de Salud Carlos III), Joan O’Donnell(Health Service Executive), Neus Latorre‐Margalef(Public Health Agency of Sweden), Camino Trobajo‐Sanmartín(Instituto de Salud Pública de Navarra), Noémie Sève(Inserm), Ivan Mlinarić(Hrvatski zavod za javno zdravstvo), Iván Martínez‐Baz(Instituto de Salud Carlos III)
Influenza and Other Respiratory Viruses
November 1, 2024
Cited by 14


Related Papers